Proton magnetic resonance spectroscopy of patients with parkinsonism

Brain Research Bulletin

Volumn 52, Issue 6, 2000, Pages 589-595

  Abe, Kazuo ^a,b   Terakawa, Haruhiko ^a   Takanashi, Mayako ^a   Watanabe, Yoshiyuki ^a   Tanaka, Hisashi ^a   Fujita, Norihiko ^a   Hirabuki, Norio ^a   Yanagihara, Takehiko ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

1H MRS; Frontal lobe dysfunction; N acetylaspartate (NAA); Parkinsonism; Proton magnetic resonance spectroscopy

Indexed keywords

CHOLINE DERIVATIVE; CREATINE; CREATINE PHOSPHATE; N ACETYLASPARTIC ACID;

ADULT; AGED; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DISEASE SEVERITY; FEMALE; FRONTAL LOBE; HUMAN; MALE; PARKINSON DISEASE; PARKINSONISM; PATIENT MONITORING; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTON NUCLEAR MAGNETIC RESONANCE; PUTAMEN; SHY DRAGER SYNDROME;

AGED; FEMALE; FRONTAL LOBE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PARKINSONIAN DISORDERS; PROTONS; PUTAMEN;

EID: 0033838752     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(00)00321-X     Document Type: Article

References (63)

1. Abe, K.; Nishikawa, Y.; Fujimura, H.; Toyooka, K.; Kaido, M.; Yorifuji, S.; Yanagihara, T. Clinical and magnetic resonance image correlation in idiopathic cerebellar ataxia. J. Neurol. Sci. 133:53-60; 1995.
2. Abe, K.; Terakawa, H.; Takanashi, M.; Yanagihara, T. Proton magnetic resonance spectroscopy of patients with parkinsonism. Ann. Neurol. 44:452; 1998.
3. Albert, M.; Feldman, R. G.; Willis, A. L. The 'subcortial demeentia' of progressive supranuclear palsy. J. Neurol. Neurosurg. Psychiatry 37:121-130; 1974.
4. Albert, M. S.; Lafleche, G. Neuropsychological testing of memory disorder. In: Yanagihara, T.; Petersen, R. C., eds. Memory disorders: Research and clinical practice. New York: Marcel Dekker; 1991:65-193.
5. Barker, P. B.; Breiter, S. N.; Soher, B. J.; Chatham, J. C.; Forder, J. R.; Samphilipo, M. A. Quantitative proton spectroscopy of canine brain: In vivo and in vitro correlations. Magn. Reson. Med. 32:157-163; 1994.
6. Birken, D. L.; Oldendorf, W. H. N-acetyl-L-aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci. Biobehav. Rev. 13:23-31; 1989.
7. Blin, J.; Baron, J. C.; Dubois, B.; Pillon, B.; Cambon, H.; Cambier, J.; Agid, Y. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch. Neurol. 47:747-752; 1990.
8. Blin, J.; Vidailhet, M.-J.; Pillon, B.; Dubois, B.; Feve, J.-R. Corticobasal degeneration: Decreased and asymmetrical glucose consumption as studied by PET. Mov. Disord. 7:348-354; 1992.
9. Bowen, B. C.; Block, R. E.; Sanchez-Ramos, J.; Partany, P. M.; Lampman, D. A.; Murdoch, J. B. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. Am. J. Neuroradiol. 16:61-68; 1995.
10. Calne, D. B.; Snow, B. J.; Lee, C. Criteria for diagnosing Parkinson's disease. Ann. Neurol. 32:8125-8127; 1992.
11. Calne, D. B.; Snow, B. J. PET imaging in Parkinsonism. Adv. Neurol. 60:484-487; 1993.
12. Clarke, C. F.; Lowry, M.; Horsman, A. Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy. Mov. Disord. 12:297; 1997.
13. Collins, S. J.; Ahlshog, J. E.; Parisi, J. E.; Maraganore, D. M. Progressive supranuclear palsy: Neuropathological based diagnostic clinical criteria. J. Neurol. Neurosurg. Psychiatry 58:167-173; 1989.
14. Couider-Khouja, N.; Vidailhet, M.; Bonnet, A. M.; Pichon, J.; Agid, Y. "Pure" striatonigral degeneration and Parkinson's disease: A comparative clinical study. Mov. Disord. 10:288-294; 1995.
15. Cummings, J. L.; Benson, D. F. Subcortical dementia. Review of emerging concept. Arch. Neurol. 41:874-879; 1984.
16. Davie, C. A.; Wennmg, G. K.; Barker, G.; Torts, P. S.; Kendall, B. E.; Quinn, N. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann. Neurol. 37:204-210; 1995.
17. Eidelberg, D.; Dhawan, V.; Moeller, J. R.; Sidtis, J. J.; Ginos, J. Z.; Strother, S. C. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J. Neurol. Neurosurg. Psychiatry 54:856-862; 1991.
18. Fahn, S.; Elton, R. L. The UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn, S.; Marsden, C. D.; Calne, D. B.; Goldstein, M., eds. Recent developments in Parkinson's disease. Vol 2. Florh: Macmillan Health Care Information; 1987.
19. Federico, F.; Simone, I. L.; Lucivero, V. Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders. Mov. Disord. 12:903-909; 1997.
20. Florham-Park, N. J.: Macmillan Health Care Information. 1987:153-164.
21. Gelb, D. J.; Oliver, E.; Gilman, S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56:33-39; 1999.
22. Folstein, M. F.; Folstein, S. E.; Mchugh, P. R. Mini-Mental State Examination: A practical method for grading the mental state of patients for clinician. J. Psychiatr. Res. 12:189-198; 1975.
23. Gibb, W. R. G. Neuropathology of Parkinson's disease and related syndromes. Neurol. Clin. 10:361-376; 1992.
24. Gill, S. S.; Small, R. K.; Thomas, D. G.; Patel, R.; Porteous, R.; Van Bruggen, N. Brain metabolies as 1H NMR markers of neuronal and glial disorders. NMR Biomed. 2:196-200; 1989.
25. Hachinski, V. C.; Iliff, L. D.; Zilhka, E.; DuBoulay, G. H.; McAllister, V. L.; Marshall, J.; Ross-Russell, R. W.; Symon, L. Cerebral blood flow in dementia. Arch. Neurol. 32:632-637; 1975.
26. Hauw, J.-J.; Daniel, S. E.; Dickson, D.; Horoupian, D. S.; Jellinger, K.; Lantos, P. L. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 44:2015-2019; 1994.
27. Hirono, N.; Yamadori, A.; Kameyama, M.; Mezaki, T.; Abe, K. Spinocerebellar degeneration (SCD): Cognitive disturbances. Acta Neurol. Scand. 84:226-230; 1991.
28. Holshouser, B. A.; Komu, M.; Moller, H. E.; Zijlmans, J.; Kolem, H.; Hinshaw, D. B. Jr. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: A multicenter pilot study. Magn. Reson. Med. 33:589-594; 1995.
29. Hoehn, M. M.; Yahr, M. D. Parkinsonism: Onset, progression, and mortality. Neurology 17:427-442; 1967.
30. Hu, M. T. M.; Taylor-Robinson, S. D.; Chaudhuri, K. R.; Morris, R. G.; Clough, C.; Brooks, D. J.; Turjanski, N. Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: A proton MR spectroscopy study. J. Neurol. Neurosurg. Psychiatry 67:20-26; 1999.
31. Hughes, A. J.; Daniel, S. E.; Kilford, L.; Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases [see comments]. J. Neurol. Neurosurg. Psychiatry 55:181-184, 1992.
32. Comment in: J. Neurol. Neurosurg. Psychiatry 56:938-939; 1993.
33. Jackson, E. F. In vivo magnetic resonance spectroscopy in humans: A brief review. Am. J. Physiol. Imaging 7:146-154; 1992.
34. Kruse, B.; Barker, P. B.; van Zijl, P. C.; Duyn, J. H.; Moonen, C. T.; Moser, H. W. Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy. Ann. Neurol. 36:595-608; 1994.
35. Lang, A. E.; Bergeron, C.; Pollanen, M. S.; Ashby, E. Parietal Pick's disease mimicking cortical-basal ganglionic degeneration. Neurology 44:1436-1440; 1994.
36. Comment in: Neurology 45:1030-1034; 1995.
37. Lezak, M. D. Neuropsychological assessment, 3rd ed. New York, Oxford: Oxford University Press; 1995.
38. Litvan, I.; Agid, Y.; Jankovic, J.; Goetz, C.; Brandel, J. P.; Lai, E. C. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 46: 922-930; 1996.
39. Marie-Francoise, C.; Jill, M. D. Basal ganglia and movement disorders. Trend. Neurosci. 19:417; 1996.
40. Miller, B. L. A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed. 4:47-52; 1991.
41. Moffett, J. R.; Namboodiri, M. A.; Cangro, C. B.; Neale, J. H. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 2:131-134; 1991.
42. Moffett, J. R.; Namboodiri, M. A.; Neale, J. H. Enhanced carbodiimide fixation for immunohistochemistry: Application to the comparative distributions of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat brain. J. Histochem. Cytochem. 41:559-570; 1993.
43. Peeling, J.; Sutherland, G. High-resolution 1H NMR spectroscopy studies of extracts of human cerebral neoplasms. Magn. Reson. Med. 24:123-136; 1992.
44. Prichard, J. W.; Brass, L. M. New anatomical and functional imaging methods. Ann Neurol 32:395-400; 1992.
45. Comment in: Ann. Neurol. 33:422-423; 1993.
46. Quinn, N. Multiple system atrophy: The nature of the beast. J. Neurol. Neurosurg. Psychiatry. 57(suppl.):78-79; 1989.
47. Quinn, N. Multiple systemic atrophy. In: Marsden, C. D.; Fahn, S., eds. Movement disorders 3. London: Butterworth-Heinemann; 1994: 262-281.
48. Rajput, A. H.; Rozdilsky, B.; Rajput, A. Accuracy of clinical diagnosis in parkinsonism - A prospective study. Can. J. Neurol. Sci. 18:275-278; 1991.
49. Rinne, J. O.; Lee, M. S.; Thompson, P. D. Corticobasal degeneration. A clinical study of 36 cases. Brain 117:1183-1196; 1994.
50. Savoiardo, M.; Girotti, F.; Strada, L.; Ciceri, E. Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. J. Neural. Transm. 42(suppl.): 93-110; 1994.
51. Shinotoh, H.; Calne, D. B. The use of PET in Parkinson's disease. Brain Cogn. 28:297-310; 1995.
52. Synek, V.; Reuben, J. R.; Du-Boulay, G. H. Comparing Evans' Index and computerized axial tomography in assessing relationship of ventricular size to brain size. Neurology 17:231-233; 1979.
53. Talbot, P. R.; Snowden, J. S.; Lloyd, J. J.; Neary, D.; Testa, H. J. The contribution of single photon emission computed tomography to the clinical differentiation of degenerative cortical brain disorders. J. Neurol. 242:579-586; 1995.
54. Taylor, L. B. Localization of cerebral lesions by psychological testing. Clin. Neurosurg. 16:269-287; 1969.
55. Taylor-Robinson, S. D.; Turjanski, N.; Bhattacharya, S.; Seery, J. P.; Sargentoni, J.; Brooks, D. J.; Cox, I. J. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. Metab. Brain Dis. 14:45-55; 1999.
56. Tedeschi, G.; Litvan, I.; Bonavita, S.; Bertolino, A.; Lundbom, N.; Patronas, N. J.; Hallett, M. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 120:1541-1552; 1997.
57. Tenerry, M. R.; Crosson, B.; Deboe, J.; Leber, W. R. Stroop Neuropsychological Screening Test. Odessa FL: Psychological Assessment Resources; 1989.
58. 1H MRS) in patients with sporadic cerebellar degeneration. J. Neuroimaging 9:72-79; 1999.
59. Urenjak, J.; Williams, S. R.; Gadian, D. G.; Noble, M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J. Neurosci. 13:981-989; 1993.
60. Verny, M.; Duyckaerts, C.; Agid, Y.; Hauw, J. J. The significance of corticalpathology in progressive supranuclear palsy. Clinico-pathologicaldata in 10 cases. Brain 119:1123-1136; 1996.
61. Vion-Dury, J.; Meyerhoff, D. J.; Cozzone, P. J.; Weiner, M. W. What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy? J. Neurol. 241:354-371; 1994.
62. Wechsler, D. Wechsler Adult Intelligence Scale-Revised. Anglicized Revision. Sidcup: Psychological Corporation; 1986.
63. Yanagihara, T. Controversies in vascular dementia. Hypertension Res. 17 (suppl. 1):S103-S107; 1994.